Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (XENE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
xene · stock forecast · 22 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 22 Wall Street analysts in the past 3 months
Buy
22 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$100
Consensus
$85.00
+66.0% upside
Low
$60.00
Median: $89.5 · Last Close: $51.21
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$85.00
66.0% upside
High Target
$100
95.3%
Low Target
$60
17.2%
Current Price
$51.21
as of today
Based on analyst price targets, the XENE stock price prediction for the next 12 months ranges from $60 to $100. The consensus XENE price forecast of $85.00 implies 66.0% upside from the current price of $51.21.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $50.19 | ↓ 2.00% |
1-day model range: $50.04–$50.34. Peak: $50.34 (-2.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · XENE · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-27 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-05-12 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-05-08 | Needham | Maintains | Buy→Buy |
| 2026-05-08 | RBC Capital | Maintains | Outperform→Outperform |
| 2026-03-16 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-10 | Wells Fargo | Maintains | Overweight→Overweight |
| 2026-03-10 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-10 | Deutsche Bank | Maintains | Buy→Buy |
| 2026-03-09 | Baird | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Xenon Pharmaceuticals Inc. (XENE) stock. Of the recent 103 rating actions, 0 were upgrades and 0 were downgrades. 22 analysts currently cover XENE.
Analyst Recommendation Trends
XENE analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 4 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 99.3% YoY
Revenue Next Year
$57M
↑ 2661.9% YoY
EPS This Year
$-4.78
EPS Next Year
$-4.93
↑ 3.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast XENE EPS of $-4.78 for the current fiscal year, based on estimates from 14 analysts. The XENE revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The XENE stock forecast is supported by two independent data sources: analyst consensus ratings from 22 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus XENE price target is $85.00 (+66.0% upside), with an analyst consensus of Buy.
The XENE short-term stock prediction for tomorrow is $50.19 (-2.00%).
Xenon Pharmaceuticals Inc. trades on NASDAQ under the ticker XENE. The XENE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
XENE forecast · 8 questionsAccording to 22 Wall Street analysts, the average 12-month XENE price target is $85.00, with a high forecast of $100.00 and a low of $60.00. The median price target is shown in the chart above when available. This implies +66.0% potential upside from the current price of $51.21.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.